Drugmaker Shares Fall After Skin Cancer Drug Trial Misses Target
Shares of an unnamed drugmaker fell in premarket trading after the company reported that a late-stage clinical trial of a skin cancer medication did not meet its primary goal. The announcement came before regular market hours.
marketwatch.comShares of the drugmaker fell in premarket trading after the company said a late-stage clinical trial of a skin cancer medication did not meet its target. The company disclosed the trial result before regular market hours on Monday. No additional details about the medication or the trial design were provided in the announcement.
Trading volume in the shares increased ahead of the market open as investors reacted to the news.
Key Facts
Potential Impact
- 01
Investors may adjust positions in the drugmaker's stock based on the trial outcome.
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…